Haemonetics (HAE) Tops Q2 EPS by 7c, Beats on Revenues
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $75.00 +1.60%
Revenue Growth %: +2.3%
Financial Fact:
Net income: 0.38
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +2.3%
Financial Fact:
Net income: 0.38
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $0.48, $0.07 better than the analyst estimate of $0.41. Revenue for the quarter came in at $225 million versus the consensus estimate of $219.26 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
- ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
